Gilead Sciences posted a net income of $852m for the first quarter 2010, compared to $586.57m for the prior year period. Income from operations was $1.16bn, compared to $808.3m for the year ago period.
Product sales increased 24% to $1.79bn for the first quarter of 2010, compared to $1.45bn in the first quarter of 2009. The increase in sales was driven primarily by Gilead’s antiviral franchise, including the strong growth in sales of Atripla and continued growth in sales of Truvada, as well as the addition of Ranexa to Gilead’s commercial portfolio.